Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

38

Revenue 2017

Imbruvica

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Imbruvica was produced by Johnson & Johnson.

New data backs Merck’s segue into MS with BTK inhibitor

New data backs Merck’s segue into MS with BTK inhibitor Merck isn’t directing its BTK inhibitor at oncology, where AbbVie and Johnson &Johnson’s Imbruvica (ibrutinib) is approved for multiple blood cancers and is leading the market.

Roche files Venclexta plus Gazyva in CLL

Roche files Venclexta plus Gazyva in CLL Roche’s marketing partner AbbVie has a stake in a direct rival, Imbruvica, which it co-markets with J&J. ... In January, Imbruvica gained approval in first line treatment in combination with Gazyva, making it the f irst non-chemo combination in this

Cancer drugs and China sustain AZ’s return to growth

Cancer drugs and China sustain AZ’s return to growth BTK inhibitor Calquence (acalabrutinib) – a rival to Johnson/AbbVie's big-selling Imbruvica (ibrutinib) – could be filed for chronic lymphocytic leukaemia (CLL) before year-end extending its current use in mantle

Imbruvica and Gazyvo approved in first non-chemo CLL use

Imbruvica and Gazyvo approved in first non-chemo CLL use Imbruvica is co-marketed by J&J and AbbVie, the companies announcing full year revenues of $2.61bn and $3.59bn respectively in the recent Q4 results. ... In just a few years, Imbruvica has become an important treatment for chronic lymphocytic leukaemia.

European biosimilars hit AbbVie’s Humira revenues in Q4

European biosimilars hit AbbVie’s Humira revenues in Q4 This portfolio revenue rose steeply to $3.93bn, up 45% on a reported basis, driven by a near 40% increase in Imbruvica sales (to $3.59bn), while Venclexta revenues hit $344m ... However just last week AbbVie suffered a knock to its ambitions for

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics